who's who

3 Houston innovators to know this week

This week's Houston innovators to know includes Chris Buckner of Mainline and Austin Hill and Brad Jenkins of Seed Round Capital. Photos courtesy

This week's Houston innovators to know have all grown or started a company during the COVID-19 pandemic — a bold choice. From an esports software entrepreneur to two serial founders looking to invest in the next generation of Houston tech startups.

Chris Buckner, co-founder and CEO of Mainline

With sports offline, esports startup Mainline has seen an opportunity for growth during the COVID-19 outbreak. Photo courtesy of Mainline

While Chris Buckner has found the isolation aspect of the pandemic challenging, he shares on this week's episode of the Houston Innovators Podcast that it's actually been an extremely exciting time for his esports tournament software startup, Mainline. This year, Mainline is poised to onboard over 100 schools to their system, and, while most of those schools were lined up before the pandemic, the process has been sped up.

"Everyone is looking for how to get sports, or esports, in front of people because everyone is just missing [sports] so much," Buckner says. "We've been very fortunate to work in the industry we do."

On campuses this past spring, basketball was cut short, baseball was canceled, and football's status is currently unknown. Colleges are looking for a way to connect with and engage students, Buckner says. And, Mainline has even been able to attract interest on the professional level. Read more and strea

Austin Hill and Brad Jenkins, co-founders of Seed Round Capital

Brad Jenkins and Austin Hill have announce the launch of a growth and invetment-focused incubator for startups called Seed Round Capital. Photos courtesy of Seed Round Capital

Brad Jenkins and Austin Hill wanted to create a firm that prioritized funding for growing tech startups in Houston, so they teamed up to launch Seed Round Capital, an investment and advisory firm based in Houston and for Houston-based startups. Rather than an accelerator model, the new firm will focus on long-term support for its portfolio companies.

"Our program helps startup founders fund and scale their businesses with management guidance from seasoned entrepreneurs. In addition, founders receive training on proven business methods specially formulated by Seed Round Capital, and access to funding," Hill says in a statement to InnovationMap.

Startups can apply online to be selected to receive mentoring from Jenkins, Hill, and a network of experts involved in — or previously involved in — Entrepreneurs' Organization (EO), a local group of business leaders. Once selected, Seed Round's startups will have access to office space at The Cannon. Read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted